geloplasma
fresenius kabi polska sp.z.o.o. - Želatina/natrio chloridas/magnio chloridas/kalio chloridas/natrio laktatas - infuzinis tirpalas - 3 g/0,5382 g/0,0305 g/0,0373 g/0,336 g/100 ml - blood substitutes and plasma protein fractions
desloratadine ratiopharm
ratiopharm gmbh - desloratadinas - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistamininiai vaistai sisteminio naudojimo, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.
flixonase
glaxosmithkline dungarvan limited - flutikazono propionatas - nosies purškalas (suspensija) - 50 µg/išpurškime - fluticasone
colhot
richard bittner ag - paracetamolis/fenilefrino hidrochloridas/askorbo rūgštis - milteliai geriamajam tirpalui paketėlyje - 300 mg/5 mg/20 mg - paracetamol, combinations excl. psycholeptics
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - vaistai nuo obstrukcinių kvėpavimo takų ligų, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - vaistai nuo obstrukcinių kvėpavimo takų ligų, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
bufomix easyhaler
orion corporation - budezonidas/formoterolio fumaratas dihidratas - įkvepiamieji milteliai - 80 µg/4,5 µg/dozėje; 320 µg/9 µg/dozėje; 160 µg/4,5 µg/dozėje - formoterol and budesonide
symbicort
astrazeneca ab - budezonidas/formoterolio fumaratas dihidratas - suslėgtoji įkvepiamoji suspensija - 80 µg/2,25 µg/išpurškime - formoterol and budesonide
unasyn
pfizer italia s.r.l. - sultamicilinas - plėvele dengtos tabletės - 750 mg; 375 mg; 250 mg/5 ml - sultamicillin
dymista
viatris healthcare limited - azelastino hidrochloridas/flutikazono propionatas - nosies purškalas (suspensija) - 137 µg/50 µg/dozėje - fluticasone, combinations